The US Patent and Trademark Office (USPTO) has granted patent, number 8,409,807 to T2 Biosystems' patent application covering its T2Candida diagnostic test.
The test identifies and detects sepsis-causing Candida species from whole blood at ~1CFU/mL sensitivity in three hours.
T2 Biosystems president and CEO John McDonough said the T2MR technology identifies Candida cells directly within a blood sample, even at low copy numbers, eliminating time-consuming and costly sample preparation.
"This piece of intellectual property adds further protection for T2 Bio's breakthrough direct detection technology that we believe will have a profound impact on the diagnostic landscape for any molecular, immunoassay or hemostasis target," McDonough added.
T2 Bio has rights to over 20 patents, protecting several of the company's assets, including its T2MR technology, T2Dx instrument and various applications of the technology.
